Company intelligence / Profile preview

Pharmacopeia

Ownership: Private
Development stage: Phase 2

Overview

At acquisition time in late 2008, Pharmacopeia had a broad portfolio of clinical and preclinical candidates with nine compounds in Phase 1 or Phase 2 addressing multiple indications. The company had strategic alliances with major pharma companies and was leveraging its integrated drug discovery platform to sustain pipeline growth.

Therapeutic areas: NephrologyPulmonologyImmunologyHematologyNeurology
Modalities: Small molecule therapeuticsSmall molecule combinatorial chemistry
Industry: Biotech

Partnerships

Bristol-Myers SquibbCelgeneCephalonGlaxoSmithKlineSchering-PloughWyeth Pharmaceuticals

Beyond the preview

Go deeper on Pharmacopeia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmacopeia.

Explore the full profile